These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 31145524

  • 1. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A, Demir G, Bekiroglu N.
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [Abstract] [Full Text] [Related]

  • 2. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M, Raap U, Staubach P, Richter-Huhn G, Bauer A, Oppel EM, Hillen U, Baeumer D, Reinhardt M, Chapman-Rothe N.
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J, Maurer M.
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [Abstract] [Full Text] [Related]

  • 7. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
    Kolkhir P, Laires PA, Salameh P, Asero R, Bizjak M, Košnik M, Dissemond J, van Doorn M, Hawro T, Kasperska-Zajac A, Zajac M, Kocatürk E, Peter J, Parisi CAS, Ritchie CA, Kulthanan K, Tuchinda P, Fomina D, Kovalkova E, Khoshkhui M, Kouzegaran S, Papapostolou N, Du-Thanh A, Kamegashira A, Meshkova R, Vitchuk A, Bauer A, Grattan C, Staubach P, Bouillet L, Giménez-Arnau AM, Maurer M, Weller K.
    J Allergy Clin Immunol Pract; 2023 Feb; 11(2):610-620.e5. PubMed ID: 36481420
    [Abstract] [Full Text] [Related]

  • 8. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A, Ergun T, Gimenez-Arnau AM.
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [Abstract] [Full Text] [Related]

  • 9. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
    Can PK, Etikan P, Degirmentepe EN, Kocaturk E.
    Asian Pac J Allergy Immunol; 2024 Jun; 42(2):132-137. PubMed ID: 33638627
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
    Cakmak ME, Yeğit OO, Öztop N.
    Int Arch Allergy Immunol; 2023 Jun; 184(3):236-242. PubMed ID: 36543155
    [Abstract] [Full Text] [Related]

  • 11. Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
    Apalla Z, Sidiropoulos T, Kampouropoulou E, Papageorgiou M, Lallas A, Lazaridou E, Smaragdi M, Delli F.
    Eur J Dermatol; 2020 Dec 01; 30(6):716-722. PubMed ID: 33258453
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jia HX, He YL.
    Am J Ther; 2020 Dec 01; 27(5):e455-e467. PubMed ID: 32427616
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study.
    Hide M, Fukunaga A, Suzuki T, Nakamura N, Kimura M, Sasajima T, Kiriyama J, Igarashi A.
    Allergol Int; 2023 Apr 01; 72(2):286-296. PubMed ID: 36272899
    [Abstract] [Full Text] [Related]

  • 15. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
    Hoşgören-Tekin S, Eyüboğlu İP, Akkiprik M, Giménez-Arnau AM, Salman A.
    Arch Dermatol Res; 2024 May 25; 316(6):261. PubMed ID: 38795119
    [Abstract] [Full Text] [Related]

  • 16. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M, Costa C, Gimenez Arnau A, Guillet G, Labrador-Horrillo M, Lapeere H, Meshkova R, Savic S, Chapman-Rothe N.
    Clin Exp Allergy; 2020 Oct 25; 50(10):1166-1175. PubMed ID: 32735720
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F, Becherel PA, Pralong P, Outtas O, Ruer-Mulard M, Berard F, Greco M, Lacour JP, Debons-Peyroutet M, Pelvet B, Lamirand A, Guillet G.
    Eur J Dermatol; 2021 Apr 01; 31(2):217-224. PubMed ID: 34001470
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
    Yang, Yu R, Qian W, Zheng Q, Xiong J, Chen S, Chen A, Chen J, Fang S, Huang K, Cai T.
    Int Arch Allergy Immunol; 2023 Apr 01; 184(7):643-655. PubMed ID: 36996780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.